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Abstract 
Lewy body (LB) disorders, including Parkinson’s disease (PD), Parkinson’s disease dementia (PDD) 
and dementia with Lewy bodies (DLB) are the second most common type of neurodegenerative 
dementia. Although the pathological hallmarks of LB disorders are Lewy bodies and Lewy neurites, 
cortical amyloid-beta (Aβ) deposition is also often seen. The relationship between Aβ pathology and 
dementia in LB disorders is unclear. Recently, PET Aβ ligands have been developed that enable in 
vivo imaging of Aβ. In this paper we review amyloid imaging studies in LB disorders. 
LB disorders are associated with lower mean cortical Aβ ligand binding compared with Alzheimer’s 
Disease. In DLB and PDD many subjects have normal levels of cortical Aβ, though a subset show 
increased Aβ ligand binding. Those with DLB show greater ligand binding than PDD; binding does not 
appear to be increased in PD without dementia. Cortical Aβ deposition may be a factor in the 
development of cognitive impairment in some cases of dementia in LB disorders. Amyloid imaging is 
of limited use in the diagnosis of LB disorders but Aβ deposition may predict the future development 
of dementia in PD. Reports of correlation between Aβ deposition and symptom profile, severity and 
progression have been inconsistent. Some results suggest a synergistic interaction between Aβ and 
α-synuclein. 
Interpretation of the current evidence is hampered by differing methodologies across studies, and 
small sample sizes. Large, prospective longitudinal studies are needed to clarify the association of Aβ 
with symptom development, progression, severity and treatment response in LB disorders. 
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Objective 
Lewy body (LB) disorders include Parkinson’s disease (PD) and the Lewy body dementias, dementia 
with Lewy bodies (DLB) and Parkinson disease dementia (PDD). Following Alzheimer’s disease (AD), 
LB dementias are the second most common cause of neurodegenerative dementia, with DLB alone 
accounting for around 15% of cases at post-mortem (1) and 10% in clinical samples (2), and high 
rates of dementia observed in PD (3). DLB and PDD are both characterised by dementia syndromes 
with specific associated symptoms including parkinsonism, fluctuating cognition and visual 
hallucinations (3, 4). Based on international consensus, DLB is diagnosed when dementia develops 
without parkinsonism or within a year of the development of parkinsonism; PDD is diagnosed when 
parkinsonism precedes dementia by more than one year (3, 4). There are no other major clinical 
differences between DLB and PDD, and despite some controversy surrounding the ‘one-year rule’ 
they are generally recognised to be on a continuum of LB disease (5). 
The pathological hallmarks of LB disorders are Lewy bodies and Lewy neurites, but many cases also 
display AD pathology (amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs)) post-mortem (6). 
The importance of AD pathology in LB disorders and its relationship to cognitive impairment is 
unclear. Post-mortem studies of confirmed DLB cases have reported that concurrent AD pathology 
measured by increased NFTs was associated with a lower likelihood of visual hallucinations and a 
lower chance of a DLB diagnosis during life (7, 8). A combination of AD and LB pathology in dementia 
is associated with a lower occurrence of parkinsonism and hallucinations compared with LB 
pathology alone (9). Greater cortical Aβ pathology has been associated with increased cognitive 
impairment (10) and a shorter time from onset of parkinsonian symptoms to cognitive impairment 
(11-13) in LB disorders. DLB has been associated with a greater Aβ burden than PDD and PD (12, 14, 
15). It has been suggested that the co-occurrence of AD and LB pathology represents more than 
coincidence, and that there may be synergism, with Aβ increasing the propensity of α-synuclein to 
accumulate and aggregate (16). 
Post-mortem studies are by their nature cross sectional and tend to report end-stage disease. Thus 
patients with initial ‘pure Lewy body pathology’ may be found post-mortem to have significant AD 
pathology, although this may not have been related to their initial presentation. PET amyloid 
imaging, initially with 11C-PiB (Pittsburgh compound B) and now with 18F labelled compounds, was 
developed to measure brain Aβ burden in vivo (17). Post-mortem studies have demonstrated that 
amyloid imaging with these ligands correlates well with Aβ deposition in the form of neuritic and 
diffuse plaques, and amyloid angiopathy (18-20). Aβ deposition in vivo is consistently elevated in AD, 
and also in some healthy control subjects (21, 22). The objective of this paper was to review all 
studies to date that have involved amyloid imaging in LB disorders to examine the contribution of Aβ 
pathology to these disorders. 
Terminology in this research field has been a subject of some debate (5). In this paper we use the 
terminology accepted by recent consensus statements (3, 4). ‘DLB’ refers to dementia with Lewy 
bodies, where cognitive impairment emerged at the same time, or within a year of parkinsonian 
symptoms. ‘PDD’ refers to Parkinson’s disease dementia, where cognitive impairment developed 
over a year after parkinsonian symptoms. ‘LB dementias’ refers to both DLB and PDD. ‘LB disorders’ 
refers to all LB pathologies (in this paper generally PD (+/- MCI), PDD and DLB). 
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Methods 
A MEDLINE (Web of Knowledge; 1950-present) search was carried out in January 2013. The search 
algorithm used was: (“Amyloid”) AND (“Positron emission tomography” OR “PET”) AND (“Lewy” OR 
“Parkinson disease”). Each word was entered both as a ‘topic’ and ‘MeSH’ term; lemmatization was 
used. 82 English-language results were found. Titles and abstracts were then screened by two 
reviewers (PD and AT) to identify studies that performed amyloid brain imaging in patients with 
Lewy body disease. A total of 16 studies with original data were identified (Table 1 summarises these 
papers). Four papers reporting post-mortem findings in patients who had ante-mortem amyloid PET 
scans were also included. Two further ‘In Press’ studies available online came to the authors’ 
attention and were included. Reference lists from the selected articles were searched for any 
additional references not captured by the search, though none were found.  
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Results 
Dementia with Lewy bodies 
When compared with healthy controls, four studies found DLB to be associated with significantly 
greater cortical and subcortical 11C-PiB binding on PET imaging (23-26). A 32% greater uptake was 
found in one study (23), although 6 controls with raised 11C-PiB binding had been excluded from 
analysis, as the aim of the study was to examine patterns of raised Aβ deposition in LB disorders. 
Two studies failed to find a significant difference between DLB and controls in global or regional Aβ 
ligand binding (27, 28). In both, DLB displayed greater binding (mean cortical binding potential: 0.18 
v. 0.08 (27); neocortex standardised uptake value ratio: 1.38 v. 1.26 (28)). It should be noted that 
these studies contained smaller DLB samples (n= 6 and n= 7 respectively) than those that found 
significant differences (n= 8-21 (23-26)). 
Particular areas of increased Aβ ligand binding have included frontal, parietal and cingulate areas, 
along with the striatum  (24-26, 29, 30), with relative sparing of the medial temporal lobe (24, 26, 
30). 
 
Four studies have compared amyloid brain imaging in DLB and AD. The largest study (n=42) found 
global 11C-PiB retention ratio to be significantly lower in DLB (26).  Two other studies have also found 
lower cortical Aβ ligand binding in DLB compared with AD (28, 30) (distribution volume ratio: 1.7 v. 
2.0 (30); standardised uptake value ratio: 1.38 v. 1.93 (28)).  
One study found no difference between DLB and AD, with very similar results in both groups in all 
cortical areas (24). In this study, the DLB group was on average 9 years older than the AD group, with 
significantly greater cognitive impairment, although results held after adjusting for age, though not 
cognition, in multivariate analysis. 
 
Gomperts et al. (25) compared DLB with the other Lewy body disorders: PDD, PD with mild cognitive 
impairment (PD-MCI) and PD. The study compared precuneus 11C-PIB retention, as retention was 
particularly high in this region and correlated very highly with global retention (r=0.939) (25). Mean 
precuneus 11C-PiB distribution volume ratio was significantly higher in DLB than the other Lewy body 
disorders (DLB=1.49, PDD=1.28, PD-MCI=1.16, PD= 1.16). This echoed their earlier findings of higher 
global cortical 11C-PiB retention in DLB (24). Edison et al. (23) also reported higher 11C-PiB binding in 
DLB compared with PDD and PD, but did not report direct statistical testing between the groups. 
Another study comparing 3 DLB patients and 3 with multiple systems atrophy (MSA) found higher 
cortical 11C-PiB binding in the DLB group (29). 
Two studies found no difference in Aβ ligand binding between DLB and PD (28) (cortical standardised 
uptake value ratio: DLB=1.38, PD=1.14); or PD, PD with MCI and PDD (27) (mean cortical binding 
potential: DLB=0.18, PDD=0.11, PD-MCI=0.08, PD=0.04). In both studies, although not significant, Aβ 
ligand binding in the groups bore the same relationship to each other seen in studies that did find a 
significant difference (DLB>PDD>PD). 
When present, the pattern of Aβ ligand binding in Lewy body disorders is similar to that seen in AD 
(24, 26, 30-34), although one study found occipital cortex binding relative to overall binding to be 
lower in AD (24). 
 
Some studies divided each diagnostic group into Aβ positive and Aβ negative subgroups, based on a 
defined threshold of Aβ ligand binding. There was a consistent finding of higher rates of Aβ positive 
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subjects in AD than DLB, in DLB than PDD, and in PDD than controls or PD (Overall average: AD=78%, 
DLB=57%, PDD=35%, control=21%, PD=13%; Table 2). The findings of PD versus controls were 
variable, with some finding higher rates in PD (24, 27), others in controls (23, 28, 35). 
Comparison across studies, and the amalgamation of data used here, should be treated with some 
caution as studies used different outcome measures (binding potential, distribution volume ratio, 
standardised uptake value ratio, visual inspection) and perhaps more importantly set different 
criteria for identifying cases as Aβ positive or negative (some looked at whole cortex average, in 
others increased Aβ in one cortical area sufficed). For example, 7 of the 8 total Aβ positive PD 
patients came from one study that accounted for only 18% of the total PD group (24). 
Recruitment practices should also be taken into account. For example, some studies selected 
patients well known to the investigators with no sign of cognitive impairment (36) or patients with 
particularly characteristic symptoms (30). Whilst this is understandable, particularly in studies where 
sample sizes are likely to be low or where aetiopathological differences between disorders are being 
investigated and thus ‘pure’ cases are sought, it does mean that the samples may not necessarily be 
representative of the total population with that disease. 
 
 
Parkinson disease dementia 
All 6 studies comparing Aβ ligand binding in PDD and controls have found no significant difference 
between the two groups (23-25, 27, 31, 35). Foster et al. found a mean cortical binding potential of 
0.11 in PDD compared with 0.08 in controls (27). In general PDD results were very similar to controls, 
with a tendency toward a small number of outliers in the PDD group with high levels of cortical Aβ 
(23, 25, 27, 33). 
Maetzler et al. (31) compared PDD and AD after removing 2 PDD patients with markedly raised 11C-
PiB binding that they felt indicated a different disease entity to ‘pure’ PDD.  The remaining PDD 
subjects demonstrated remarkably similar cortical Aβ binding to the control group and lower cortical 
and striatal binding than the AD group .The two high 11C-PiB binding subjects had an ‘AD-like’ 
pattern of deposition. The only other study to compare PDD and AD found no outlying PDD subjects, 
with Aβ ligand binding significantly lower in PDD than AD (24). 
 
Several studies have noted no significant difference in Aβ binding between PDD and PD (23-25, 27, 
35) or PD with MCI (25, 37) However, PDD consistently has a greater proportion of Aβ positive 
subjects when groups are divided in a binary fashion as positive or negative (Table 2). 
Relevant to this, Petrou et al. (32) identified 40 patients with PD at risk for dementia (with MCI/older 
age /long duration of PD/prominent gait or balance impairments). On further testing 5/40 subjects 
were diagnosed as having mild dementia. When the subjects underwent amyloid imaging 4/5 
subjects with dementia had elevated 11C-PiB binding on visual inspection, compared with 2/30 
patients with PD-MCI and 0/5 with PD and some other risk factor for dementia. This finding of 
increased rates of Aβ positive subjects in PDD groups compared with PD or controls, without any 
difference in mean cortical Aβ ligand binding, may be accounted for by a subgroup of outlying PDD 
subjects with high Aβ binding (23, 25, 27, 33), or a different pattern of deposition in PDD that results 
in focal increases in binding without a significantly increased overall Aβ load (24). 
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Parkinson Disease 
7 studies have compared amyloid imaging findings in PD and controls. One small study compared a 
group of PD patients with controls from a previous study and found the PD group had significantly 
lower 11C-PiB binding in the frontal (11C-PiB uptake/cerebellum: 1.10 v 1.30), parietal (1.15 v 1.35) 
and posterior cingulate (1.04 v 1.43) cortices (36).  The PD subjects were well known to the 
investigators, with no evidence of cognitive impairment on routine assessment. It may be that they 
represented a subgroup of particularly cognitively healthy individuals. 
Other studies have found no difference between PD and controls (23-25, 27, 28, 35), although mean 
cortical Aβ ligand binding was marginally lower in PD in some (25, 27, 28) (mean cortical binding 
potential: 0.04 v 0.08 (27), standardised uptake value ratio: 1.14 v 1.26 (28)). Edison et al. found 
similar 11C-PiB uptake in all brain areas (0-4% higher in PD than controls) although 6 11C-PiB positive 
subjects were removed from the control group before analysis (23). 
Three studies comparing PD with AD have all found lower brain Aβ ligand binding in PD (24, 28, 36). 
 
 
Relationship between Aβ and clinical picture 
Cognitive impairment and dementia severity 
Two studies have found a significant correlation between MMSE score and Aβ ligand binding when 
analysing data across multiple disease groups (DLB, PDD, PD: r=-0.5, p=0.01, n=26 (24); DLB, PD, AD, 
MCI, FTLD, VaD, controls: r=-0.49, p<0.0001, n=109 (28)). However, over both studies, only the MCI 
group in Villemgne et al. (28) displayed the same correlation within the group (r=-0.76, p<0.0001, 
n=20). 
Other studies have considered PDD/DLB as a single group for analysis. In such a group the Aβ 
positive subjects were found to have a significantly lower MMSE than the Aβ negative group, but 
this group was also older (33). Conversely, Foster et al. (27) were not able to identify differences 
between Aβ positive and negative PDD/DLB groups in MMSE, NPI or cognitive fluctuations. However, 
pooling the Aβ positive and Aβ negative PDD/DLB subjects (n=21) they found mean cortical and 
caudate Aβ binding correlated modestly with MMSE (cortical: r=-0.47, p=0.04; caudate: r=-0.44 
p=0.05) and CDR global (cortical: r=0.55, p=0.01; caudate: r=0.51, p=0.02). No such correlation 
existed in PD or control groups. In PD with MCI, MMSE correlated strongly with caudate Aβ (r=-0.82, 
p=0.007, n=9) but not mean cortical Aβ (p=0.52).  
 
In a population mostly consisting of PD-MCI, Aβ ligand binding was found to correlate with global 
cognitive scores (r=-0.55, p=0.0006, n=40) and Wechsler Adult Intelligence Scale score (r=-0.54, 
p=0.0004, n=40) (32). However these results may have been strongly influenced by 4 PDD subjects 
with high levels of brain Aβ and cognitive impairment. 
In a DLB-only group, Gomperts et al. (25) found increased Aβ ligand binding to be associated with 
lower MMSE (p<0.001) scores and worse semantic memory (p=0.001). No such association was 
found in PDD, PD, PD-MCI or controls. Other studies have found no relationship between Aβ and 
MMSE (23, 34) or dementia severity measured by CDR (26) in DLB. 
 
One longitudinal study in 46 PD subjects with either MCI or no cognitive impairment found that 
baseline increased precuneus 11C-PiB binding was related to decline in executive function (p=0.035), 
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weakly related to decline in visuospatial function (p=0.06), and associated with a greater likelihood 
of transition to MCI or dementia (p=0.035) (37). 
In summary, there is conflicting evidence surrounding the association of amyloid deposition with 
increased cognitive impairment in LB disorders. Where correlation has been reported, it has 
generally been modest, and often in samples containing disparate diagnostic groups. Further 
research is needed to clarify the association of amyloid deposition with cognitive impairment in each 
of the LB disorders.    
 
Parkinsonism 
In DLB and PDD, but not PD, higher relative Aβ ligand binding in the striatum (adjusted for overall 
binding) was associated in one study with better motor performance as measured by the UPDRS 
(DLB: r=-0.87, p=0.01, n=8; PDD: r=-0.90, p=0.005, n=7) (24). Other studies have found no correlation 
between global cortical (26, 27, 33, 34) or precuneus (25) Aβ binding and motor impairment. 
However, these studies did not report specifically assessing relative striatal binding. A longitudinal 
study found that baseline striatal or precuneus amyloid ligand binding in PD and PD-MCI did not 
predict future motor deterioration (37). 
 
Hallucinations and visuospatial ability 
In the two studies which have reported this, no relationship has been found between mean cortical 
(26) or occipital (24) Aβ binding and hallucinations. 
In DLB, PDD and PD, but not AD or controls, relative parietal/posterior cingulate (but not occipital) 
binding was associated with impaired visuoperceptual ability as measured by the Benton visual form 
discrimination test (24). 
 
 
Fluctuations 
Fluctuations, measured using the Mayo Fluctuations Questionnaire, were not found to be associated 
with an increased Aβ ligand binding in DLB or PDD in two studies (26, 27). 
 
 
RBD 
No studies have reported investigating an association between RBD and Aβ ligand binding. 
 
 
Disease onset, progression and treatment response 
The first study of amyloid PET in DLB found that increased Aβ binding was correlated with a shorter 
time between the onset of cognitive impairment and diagnosis of DLB (r=-0.75, p=0.01, n=10), with 
no such relationship  seen in AD (30). 
Maetzler et al. (33) found that in a combined DLB and PDD group, Aβ positive patients had an older 
age at onset of parkinsonism and dementia and had lower MMSE scores. The authors suggested that 
this may be an effect of increasing Aβ with increasing age, or that cortical Aβ deposition is associated 
with different disease mechanisms resulting in an older age of onset and more rapid clinical 
progression. 
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In a small group of treatment naïve patients, Graff-Radford et al. (38) found that after treatment 
with acetylcholinesterase inhibitors Aβ positive patients (n=3)  tended to remain stable or decline, 
whereas Aβ negative patients (n=4) tended to remain stable or improve. 
 
 
Relationship with genetics, imaging findings and other biomarkers 
An early study found the apolipoprotein E4 (ApoE4) genotype was associated with increased 11C-PiB 
binding across groups (including relatively large groups of AD and controls) but not within diagnostic 
groups (30). Similarly, in a large study, Gomperts et al. (25) found that ApoE4 genotype and 11C-PiB 
binding were correlated across the entire cohort (DLB, PDD, PD-MCI, PD, controls; r=0.49, p<0.0001). 
In a study involving DLB, PDD and PD subjects, the Aβ positive group (all of whom had dementia) 
were found to have increased rates of the ApoE4 allele and lower CSF Aβ-42 concentrations 
compared with Aβ negative patients (33). These results are consistent with findings in AD subjects, 
those with MCI and apparently healthy older controls, that the ApoE4 genotype is robustly 
associated with increased Aβ binding (39, 40). 
In a recent study, Shimada et al. (34) examined the association between 11C-PiB binding and cortical 
atrophy in a combined PDD/DLB group compared with AD and healthy controls. They found that of 
6/15 PDD/DLB patients were 11C-PiB +ve. Compared to 11C-PiB –ve controls (11C-PiB +ve controls 
were excluded) the 11C-PiB +ve PDD/DLB group demonstrated significant cortical atrophy, 
particularly in temporal and parietal areas, whereas the 11C-PiB –ve group did not. Using volume of 
interest analysis, the 11C-PiB +ve PDD/DLB group had lower parahippocampal grey matter volume 
than 11C-PiB –ve PDD/DLB subjects. There were no differences between the two groups in cognitive 
tests. Atrophy was not correlated with Aβ ligand binding in any group. The authors commented that 
Aβ deposition in PDD/DLB appeared to be associated with cortical atrophy in a pattern similar to 
that seen in AD, though the level of atrophy itself was not correlated with amyloid load and likely 
due to down-stream effects. 
 
Three studies have compared amyloid imaging scans with 18F-FDG PET in Lewy body disorders (26, 
29, 35). Two studies in DLB and PDD reported brain hypometabolism (in areas such as the occipital 
and posterior parietotemporal lobes) in the absence of Aβ deposition and suggested that the two 
processes do not appear directly related, similar to the apparent dissociation between structural MR 
measures of atrophy and PET hypometabolism in DLB (41). One smaller study (n=3), found 
corresponding hypometabolism and amyloid deposition in several cortical areas (29). 
 
Diagnostic utility 
Some studies have investigated the diagnostic value of amyloid imaging in conjunction with other 
imaging methods. Burke et al. (42) used qualitative assessment of Aβ and dopamine transporter PET 
imaging in combination to diagnose patients with AD, DLB or FTD, and compared concordance with 
clinical diagnosis. The overall agreement was poor (κ=0.39; CI 0.18-0.61). The best agreement was 
for the diagnosis of DLB, and subjects were classified as such based solely on positive dopamine 
transporter PET results. 
In a study of 21 DLB and 21 AD patients, a combination of hippocampal volume on structural MRI, 
cortical Aβ ligand binding and occipital lobe hypometabolism on PET could differentiate between AD 
and DLB with an accuracy of 98%, with each imaging technique contributing significantly to the 
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model used (26). Amyloid PET alone had an area under the receiver operating curve (AUROC) of 0.89 
(p<0.001). 
Reviewing data from studies that provided data in the form of dot-plots (24, 28, 30), it is clear that 
even using post-hoc ideal thresholds to differentiate between AD and DLB based on amyloid ligand 
binding, specificity remains poor 50-71% (as a proportion of DLB cases have raised cortical amyloid), 
though sensitivity for AD can be up to 97% (as low amyloid in AD is rare). 
Ossenkoppele et al. (43) performed 11C-PiB and 18F-FDG PET scans on 154 patients at a specialist 
memory clinic. Clinicians were asked to make a diagnosis following clinical assessment but before 
the scans, and to express their certainty in the diagnosis. Following the scan results the diagnosis 
was reassessed. Clinical diagnosis changed in 23% of cases. Clinicians reported that 11C-PiB PET 
contributed to the diagnosis in 86% of patients, mostly as a test that may rule out AD. 
 
Reports of post-mortem examination after amyloid PET imaging 
The first post-mortem report of a patient with DLB who had had an amyloid PET scan was by Bacskai 
et al. (44). They found that amyloid imaging findings corresponded to post-mortem Aβ levels in brain 
homogenates measured using enzyme-linked immunosorbent assays. Much of the Aβ burden on 
imaging was due to cerebral Aβ angiopathy. 
 
Burack et al. (45) examined 3 patients with PDD, 2 of whom had extensive cortical 11C-PiB uptake in 
PET scans before death. Both were found to have abnormal levels of cortical Aβ (predominantly 
diffuse plaques) post-mortem. All cortical areas with PET mean cortical binding potential greater 
than 0.2 had severe plaque burden post-mortem. The case with no raised Aβ binding had minimal 
Aβ plaques but abundant cortical Lewy bodies, suggesting there is no significant binding of 11C-PiB to 
LBs during amyloid PET scans. 
 
Kantarci et al. (26) reported 3 cases of DLB with ante-mortem amyloid imaging. One had raised 
cortical 11C-PiB binding (11C-PiB retention ratio >1.6) and two had borderline binding (11C-PiB 
retention ratio 1.4-1.6). The case with raised 11C-PiB had sparse neuritic plaques but frequent diffuse 
plaques. The two borderline cases had sparse or moderate neuritic plaques (the level of diffuse 
plaques was not mentioned). 
The case with raised 11C-PiB underwent quantitative comparison of amyloid deposition measured by  
11C-PIB PET and post-mortem image analysis of immunostains of corresponding regions (46). There 
was a strong correlation between 11C-PiB retention (18 months ante-mortem) and post-mortem Aβ 
density in the 17 ROIs analysed (r=0.899; p < 0.0001). Lewy body and tau density did not correlate 
with 11C-PiB retention. 
Ikonomovic et al. (47) examined a case of probable DLB with a negative 11C- PiB PET scan. Although 
post-mortem examination did identify Aβ plaques, they were infrequent and primarily diffuse rather 
than neuritic. The authors commented that the level of amyloid deposition necessary to elicit a 
positive 11C-PiB PET scan is not yet clear. Post-mortem Aβ42 concentration in brain homogenates 
correlated with 11C-PiB retention in the ante-mortem PET scan (r=0.72, p=0.009), corroborating the 
finding of Kantarci et al. (26) above. 
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Conclusions 
Differences between diagnostic groups 
In summary, all Lewy body disorders are generally associated with lower mean cortical Aβ ligand 
binding than AD. DLB is usually associated with higher mean cortical Aβ binding than PDD, PD or 
controls. There are no significant differences between PDD, PD and controls. When Aβ is present, 
the pattern of deposition in LB disorders is similar to that seen in AD, with deposition in frontal, 
parietal and cingulate areas, along with the striatum. Only one study used an 18F-labelled tracer 
(Florbetaben) (28), all other studies used 11C-PiB. The pattern of cortical binding with 18F-Florbetaben 
was almost identical to that of 11C-PiB, though to a slightly lesser degree (28). 
 
Some differences between diagnostic groups only become evident when subjects are classified as Aβ 
positive or negative based on a defined threshold. In most studies directly comparing rates of Aβ 
positive subjects in each diagnostic group (Table 2), AD had higher rates than DLB, which in turn had 
higher rates than PDD, which had higher rates than PD or controls. Between PD and controls there 
was more variability, with controls having higher rates of Aβ positive subjects in 3 of 5 studies in 
which they were directly compared. From these findings we can conclude that whilst Aβ deposition 
in itself is neither necessary nor sufficient for the development of dementia in LB disorders, the 
presence of Aβ is more common in those with dementia, and relatively rare in those without 
dementia. These findings mirror results from post-mortem studies that have found greater Aβ 
deposition in DLB than PDD or PD (11, 12, 48, 49), and higher deposition in PDD than PD (48, 50, 51). 
 
High levels of cortical Aβ are unusual in PD. Petrou et al. (32) found that most of the small number of 
patients with Aβ positive PET scans in a PD cohort identified for being at risk of dementia actually, on 
closer examination, already had dementia. Similarly, in a post-mortem study of 129 cases of PD, 17 
of 20 of patients that had Aβ plaque pathology rated CERAD (52) grade B or C had dementia (85% v. 
54% in the overall group) (53). In another neuropathological study of 200 patients with an initial 
diagnosis of PD, higher CERAD scores were found almost exclusively in patients who developed 
dementia (CERAD scores PD: B=3%, C=0%; PDD: B=51%, C=33%) (54).  
 
Diffuse neocortical or limbic Lewy body pathology is generally seen as the main substrate of 
dementia in LB disorders (3, 51, 55). The findings above suggest that the presence of Aβ confers a 
higher risk for the development of dementia in LB disorders. A possible explanation for this is that 
the combination of cortical Aβ and Lewy body pathology may have synergistic effects. Some post-
mortem studies have found that increased Aβ is associated with increased α-synuclein levels in the 
brain in Lewy body disorders and AD (16, 50, 56), although other studies have contradicted this (55, 
57) 
Interestingly, Aβ promotes the formation of α-synuclein oligomers and polymers in vitro (58). 
Experiments in transgenic mice expressing human Aβ, tau and α-synuclein peptides have shown that 
the presence of Aβ increases the formation of α-synuclein neuronal inclusions (58) and α-synuclein 
increases the deposition of both Aβ and tau (59). 
Thus, in LB disorders, the presence of significant Aβ may lead to a synergistic interaction with α-
synuclein, resulting in widespread deposition of α-synuclein and Aβ, leading to cognitive 
impairment. This hypothesis may help explain the infrequency of significant Aβ deposition in PD 
without cognitive impairment and the increased rates of Aβ seen in DLB compared with PDD, as DLB 
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by definition demonstrates dementia (an indicator of widespread neurodegeneration) earlier in the 
disorder. The apparent synergistic interaction between Aβ and α-synuclein is a possible target for 
therapeutic intervention, given our ability to identify the subset of Lewy body disease sufferers with 
Aβ deposition using PET imaging. 
 
 
Relationship of Aβ to clinical picture 
In imaging studies cognitive impairment has correlated positively with Aβ ligand binding across 
diagnostic groups (24, 28). This may simply reflect that Aβ burden is high in AD and DLB and low in 
PD and controls. More interestingly, Aβ binding may be correlated with cognitive impairment in 
Lewy body dementia only-groups (27, 33) and may predict cognitive decline in PD and PD-MCI (37). 
Some pathological studies support these findings. Patients with a combination of DLB and AD 
pathology post-mortem have been found to have had worse cognitive function (10), more severe 
dementia (60) and a faster rate of cognitive decline (61) than those with ‘pure’ DLB pathology. A 
correlation between cognitive impairment and Aβ deposition in PD and PDD groups has been found 
(48, 50, 62), although this link did not survive regression modelling in some studies (62). 
Conversely, other studies have found no correlation of MMSE with CERAD score in PD with or 
without cognitive impairment (55, 63), and AD pathology in PDD has been found not to affect 
performance on MMSE or other neuropsychological tests (64). 
 
Imaging studies have found suggestive links between increased Aβ ligand binding and older onset of 
motor impairment and dementia (33), and a shorter interval between the onset of motor 
impairment and cognitive impairment (30). There have been various, often contradictory 
pathological findings about the association of Aβ deposition with disease onset and progression in LB 
disorders. 
Increased Aβ burden post-mortem has been associated with older age of onset and shorter survival 
in DLB, PD and PDD (54); and shorter duration of parkinsonism prior to the onset of dementia in PDD 
and DLB (11-13, 50, 57). Other studies found no correlation between Aβ burden age of onset, 
disease duration and age of death in DLB (10, 57) or PD (56); rate of decline in PD or PDD (55); or the 
interval between motor and dementia symptoms in PDD (51). Some even found increased Aβ to be 
associated with longer disease duration in PD, although with higher dementia scores (62). A large 
epidemiological study (65) found that the occurrence of dementia in PD was a function of age, and 
age of onset had no effect above this. Thus, in some studies (12, 50) the shorter duration of 
parkinsonism before dementia observed in Aβ positive patients could simply be a function of their 
older age. 
 
Findings from amyloid imaging studies can drive hypotheses that should then be tested in other 
imaging studies as well as pathological studies. Similarly, pathological findings (from which most of 
our current knowledge of the Aβ in LB disorders derives) will drive hypotheses in future imaging 
studies. Some other positive findings from these early imaging studies that should be tested in 
future studies include the links between striatal Aβ and Parkinsonism; parietal/posterior cingulate 
Aβ and visuoperceptual ability; and Aβ ligand binding, ApoE genotype and CSF Aβ-42. Further studies 
are also needed to corroborate the finding that the other core symptoms of DLB, visual 
hallucinations and fluctuating cognition, are not related to Aβ deposition. 
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Based on current data it is not possible to make any firm conclusions on the influence of Aβ 
pathology on disease progression and clinical phenotype in Lewy body disorders. There are a few 
reasons for this. Aβ imaging studies have thus far, with two exceptions, been cross sectional rather 
than longitudinal. Studies vary in image acquisition, processing and analysis; clinical and imaging 
outcome measures used and cut off points for Aβ positive and negative cases; recruitment source 
(i.e. movement disorder or memory clinics); entry criteria for subjects; and processing of results (e.g. 
the removal of control/PDD subjects with raised amyloid from analysis (23, 31, 34)). Few studies 
have tested the same hypotheses using comparable outcome measures. Many studies also suffered 
from low sample sizes, and sub-optimal measures such as the MMSE, which may not be sensitive to 
cognitive changes in LB disorders. These problems, and a tendency in some studies to report the 
results of statistical tests without summary data, prevented any quantitative meta-analysis of the 
results. Large-scale, prospective studies are needed to properly investigate the effect of Aβ burden 
on the onset, progression, severity and character of symptoms in LB disorders. 
 
Neuropathological studies suffer from similar inconsistencies (e.g. in the use of grading rather than 
fully quantitative measures to assess brain pathology). Comparison between imaging and 
pathological studies is difficult as amyloid PET measures both diffuse and neuritic plaques, as well as 
amyloid angiopathy, whereas most pathological studies focus solely on neuritic plaques. Although 
11C-PiB has higher affinity for neuritic plaques, diffuse plaques account for most of the in vivo binding 
in LB disorders (45, 46). 
 
Some authors have questioned the ability of PET amyloid imaging to adequately quantify amyloid 
burden, highlighting problems with current PET amyloid imaging technology including partial volume 
effects and non-specific binding of amyloid radioligands (66). 
PET imaging has a relatively low resolution compared with MRI. This results in a relatively large voxel 
size. Given the thinness of the cerebral cortex, partial volume effects (where a voxel contains signal 
from both grey and white matter, or grey matter and CSF, for instance) are possible (66). This is 
further complicated by the presence of significant cortical atrophy in a proportion of subjects with 
cognitive impairment. Although this problem is by no means unique to PET amyloid imaging, it does 
raise doubts about the ability of PET imaging to accurately quantify amyloid burden in dementia and 
highlights the importance of the use of correction measures for partial volume effects (67). Few of 
the studies reviewed here used such correction measures (Table 1).  
Amyloid radioligands, particularly 18F-labelled ligands, have high non-specific white-matter binding 
(17). Studies comparing PiB binding (in vitro and in vivo) with amyloid burden measured by 
immunohistochemistry have demonstrated that PiB does not give a direct quantitative measure of 
cortical amyloid burden (44, 68). Similarly, a study comparing in vivo PiB binding with amyloid 
burden post-mortem found cases where the precuneus was observed to have the highest PiB 
retention, despite other brain areas having markedly greater amyloid burden quantified by 
stereological assessment (69). It should be noted that, despite this, there was a strong correlation 
between 11C-PiB binding and post-mortem amyloid burden in the precuneus, anterior cingulate and 
posterior cingulate, though not the hippocampus or orbitofrontal cortex (69). Thus, although ligand 
retention and amyloid burden are correlated in different brain areas within one subject (46) and 
between subjects (19, 69), amyloid PET cannot be said to precisely quantify amyloid burden in each 
particular brain area. These issues should be borne in mind when interpreting and discussing 
amyloid PET findings. 
14 
 
  
Clinical use and diagnostic utility 
The large variability in Aβ binding found in DLB and PDD limits the use of Aβ imaging in isolation in 
the diagnosis of dementia. However, it may improve accuracy when used in conjunction with other 
biomarkers such as structural MRI and FDG-PET (26). Aβ imaging has negative predictive value in the 
diagnosis of AD, positive predictive value for the development of dementia in MCI and clinicians find 
it of use in the diagnosis of dementia, particularly where diagnostic confidence is low (43, 70). Given 
that Aβ deposition is uncommon in PD compared with PDD, amyloid imaging in PD may be useful to 
identify cognitively normal or sub-syndromal patients who will later go on to develop dementia. This 
test may be expected to have a high positive predictive value but a low sensitivity, given the 
frequent occurrence of PDD in the absence of significant Aβ pathology. In one study, 2/3 PD subjects 
with a high amyloid ligand binding later developed MCI (37). Further prospective studies are 
required to investigate this.  
 
Neuropathological studies have found that NFT pathology in DLB may be associated with a clinical 
picture more similar to AD than classical DLB (57, 71). The degree to which high Aβ binding is also 
associated with a less classical DLB clinical phenotype is of interest; such patients may have a 
different prognosis, different levels of neuroleptic sensitivity and a different response to treatment.  
There is a relative paucity of NFT pathology in LB disorders (63), but when present it is a reliable 
correlate of dementia (51, 54). Although no imaging ligands for tau are yet available, there are 
imaging correlates of tau pathology. Brain atrophy on MRI, particularly in the medial temporal lobe 
has been found to be associated with post-mortem tau pathology, measured quantitatively with tau 
antibody and image analysis or semi-quantitatively using Braak NFT staging (72-74). A recent study 
has found brain atrophy in amyloid positive, but not amyloid negative PDD/DLB subjects (34), 
despite this, atrophy was not correlated with PiB binding. This may be because atrophy is the result 
of downstream effects, either of tau, α-synuclein, a combination of both, or another factor. A 
combination of amyloid imaging and MRI measures of atrophy (as a surrogate measure of tau 
pathology) may be important in any study wishing to investigate the influence of AD pathology in LB 
disorders. 
 
To conclude, amyloid imaging studies have demonstrated that significant Aβ deposition is present in 
a proportion of DLB and PDD patients. Significant Aβ deposition appears to be relatively rare in PD. 
Dementia often occurs in the absence of Aβ, but there is some evidence that amyloid may be related 
to the onset or progression of cognitive symptoms in these disorders, though current results are not 
conclusive. Large scale, prospective amyloid imaging studies may resolve some of these unanswered 
questions and clarify the importance of Aβ in LB disorder
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Table 1. Summary of PET amyloid imaging studies excluding neuropathological case studies 
Study Population Source Scans, 
ligand 
Amyloid PET acquisition 
and image analysis 
Regions reported Major findings 
Rowe et al. 
2007 (30) 
10 DLB 
17 AD 
9 MCI 
6 FTD 
27 HC 
 
AD/DLB: memory disorders and 
neurobehavioural clinics. 
Controls: from a separate 
longitudinal study known to 
have normal cognitive function. 
MRI 
11
C-PIB PET 
90 min acquisition. ROI 
11
C-PIB DVR v. 
cerebellum.  Logan 
graphical analysis 
method. 
16 cortical and 
subcortical areas 
including overall cortex. 
PiB burden AD>DLB>HC. 
PiB burden correlated with shorter time 
from onset of symptoms to diagnosis in DLB. 
ApoE4 genotype linked to Aβ burden 
across groups. 
Edison et al. 
2008* (23) 
13 DLB* 
12 PDD 
10 PD 
41 HC 
Multicentre study (UK, Finland, 
Australia). 
 
MRI 
11
C-PIB PET 
60-90 min 
11
C-PIB uptake 
ratio; ROI v. cerebellum. 
Voxel based comparison 
with threshold p<0.001. 
6 cortical areas, striatum, 
thalamus and whole 
cortex. 
DLB more likely to show raised Aβ burden 
compared with PDD or PD. 
Gomperts et 
al. 2008 (24) 
8 DLB 
7 PDD 
11 PD 
15 AD 
37 HC 
Movement and memory units. 
AD and HC collected separately 
in another longitudinal study. 
11
C-PIB PET 60 min DVR v cerebellum. 
Logan graphical analysis 
method. 
6 cortical areas, striatum, 
whole cortex. 
PiB binding DLB>PDD/PD/HC. 
PiB binding in DLB comparable to AD. 
In LBD (DLB+PDD) relative striatal binding 
was associated with improved 
performance on UPDRS. 
Johansson et 
al. 2008 (36) 
5 PD 
16 AD 
6 HC 
AD and HC from previous study.  
PD: not stated. 
11
C-PIB PET 
11
C-L-DOPA 
PET 
40-60 min regional 
uptake volume of interest 
v. cerebellum. 
5 cortical areas, 
subcortical white matter, 
pons, striatum. 
PiB retention was greater in AD than PD in 
all cortical areas and striatum. Lower in PD 
than control in frontal, parietal and 
cingulate areas. 
Maetzler et al. 
2008 (31) 
10 PDD 
6 AD 
11 HC 
Not stated 
11
C-PIB PET 
 
42-72 min ROI SUVR v. 
cerebellum. 
Frontal cortex, posterior 
cingulate, striatum, 
thalamus, brainstem, 
cerebellum, white matter 
2/10 PDD had ‘AD-like’ pattern of amyloid 
deposition. 
Brainstem:posteriorcingulate DVR: 
PDD>control, AD, ‘AD-like’ PD. 
Maetzler et al. 
2009 (33) 
9 DLB 
12 PDD 
14 PD 
Ward/OP dept. in 
Neurodegenerative Dept. of a 
University Hospital 
11
C-PIB PET 
 
42-72 min ROI SUVR v. 
cerebellum. 
5 cortical areas, whole 
cortex, striatum 
PiB +ve patients had lower CSF Aβ42, higher 
ApoE4 allele rate, all had dementia. Within 
dementia, PiB +ve had lower MMSE scores. 
Jokinen et al. 
2010 (35) 
11 PDD 
8 PD 
24 HC 
University Hospital 
11
C-PIB PET 
18
F-FDG PET 
MRI 
60-90min 
11
C-PIB uptake 
ROI v. cerebellum. 
5 cortical areas, caudate, 
putamen 
No significant difference between groups 
in any cortical area. PDD more likely to 
show 1+ cortical areas with increased PiB 
uptake. 
Foster et al. 
2010 (27) 
6 DLB 
15 PDD 
9 PD-MCI 
8 PD 
9 HC 
Movement disorders centre 
11
C-PIB PET 
MRI 
60 min dynamic scan. 
Binding potentials of ROIs 
and MCBP. Logan 
graphical analysis, 
cerebellum as reference.  
5 cortical areas, caudate, 
mean cortex 
No differences in MCBP or regional BPs 
between groups. 
Correlation between caudate BP/MCBP 
and MMSE in some groups. 
Burke et al. 
2011 (42) 
14 DLB 
36 AD 
25 FTD 
Cognitive disorders clinic 
11
C-PIB PET 
11
C-DTBZ 
PET 
 
80 min scan. ROI DVR v. 
cerebellum. Subjective 
visual assessment. 
Frontal cortex : white 
matter DVR ratio 
Only moderate concordance between 
clinical diagnosis and diagnosis based on 
scan results. 
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Claasen et al. 
2011 (29) 
3 DLB 
3 MSA 
12 HC 
Neurology clinic 
11
C-PIB PET 
18
F-FDG PET 
MRI 
40-60 min acquisition. 
ROI v. cerebellum. 
7 cortical areas and 
caudate. 
Higher binding found in DLB in all areas. 
Most marked in prefrontal, parietal, 
temporal and precuneus. 
Villemagne et 
al. 2011 (28) 
7 DLB 
5 PD 
30 AD 
20 MCI 
11 FTD 
4 VaD 
32 HC 
Memory disorders service, 
movement disorders clinics 
18
F-
Florbetaben 
PET 
MRI 
 
90-110 min acquisition. 
ROI SUVR v. cerebellar 
cortex 
9 cortical areas, total 
cortex, 6 non-cortical 
areas. 
AD and MCI had higher neocortical and 
striatal binding than controls. No other 
significant differences between groups. 
Gomperts et 
al. 2012 (25) 
18 DLB 
12 PDD 
14 PD-MCI 
29 PD 
85 HC 
Movement disorders and 
memory disorders units. HCS 
from separate study. 
11
C-PIB PET 
 
60 min dynamic 
acquisition. Logan 
graphical analysis 
method. ROI DVR v. 
cerebellum. 
SPM analysis corrected 
for multiple comparisons 
(false discovery rate). 
Precuneus 
Voxel-wise comparison 
DLB exhibited higher binding than other 
groups, particularly in frontal and parietal 
areas. No differences found between non-
DLB groups. 
PiB burden increased in ApoE4 genotype 
across entire cohort. 
In DLB increased PiB binding was 
associated with decreased MMSE score 
and poorer semantic memory. 
Graff-Radford 
et al. 2012 
(38) 
7 DLB (of 54 
DLB) 
AD research centre 
(retrospective study of pts. 
involved in longitudinal study) 
11
C-PIB PET 
MRI 
40-60 min. ROI v. 
cerebellum. 
Partial volume correction. 
Global cortical retention. Both subjects who declined were PiB +ve; 
all 3 subjects who improved were PiB –ve. 
Kantarci et al. 
2012 (26) 
21 DLB 
21 AD 
42 HC 
DLB recruited from AD research 
centre. AD and HC from a 
longitudinal cohort. 
11
C-PIB PET 
18
F-FDG PET 
MRI 
40-60 min acquisition. 
ROI v. cerebellum. 
Voxel based comparison 
using FWE correction. 
Partial volume correction. 
Global cortical retention 
Voxel-wise comparison 
DLB PiB binding was significantly lower 
than AD but significantly higher than 
controls. 
No relationship found between global PiB 
and motor impairment, dementia rating, 
visual hallucinations or duration of 
symptoms. 
Petrou et al. 
2012 (32) 
40 PD at risk 
for 
dementia 
University based movement 
disorders subspecialty clinic 
11
C-PIB PET 
11
C-DTBZ 
PET 
MRI 
80 min acquisition. Logan 
graphical analysis 
method. 
DVR v. cerebellum. 
Mean cortical PiB DVR. 
Visual assessment. 
Cortical PiB was inversely correlated with 
overall cognitive score and WAIS score. 
Ossenkoppele 
et al. 2012 
(43) 
66 AD 
30 MCI 
15 SMC 
18 FTD 
5 DLB 
20 other 
Specialist memory disorder 
clinic. Patients mostly attending 
for second/third opinion. 
11
C-PIB PET 
18
F-FDG PET 
MRI 
90 min dynamic scan. ROI 
BP v. cerebellum. 
For 12 patients 60-90 min 
SUVR ROI v cerebellum. 
Visual assessment. 
11
C-PIB PET contributed to diagnostic 
process in 86% of patients, mainly used to 
rule out AD. 
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*Includes 10 DLB patients from Rowe et al. (30). 
DLB = dementia with Lewy bodies; PD(D) = Parkinson’s disease (dementia); AD = Alzheimer’s disease; MSA = multisystem atrophy; FTD = frontotemporal 
dementia; VaD = vascular dementia; MCI = mild cognitive impairment; HC = healthy controls; SMC = subjective memory complaint. 
PET = positron emission tomography; MRI = magnetic resonance imaging; PIB = Pittsburgh compound B; DTBZ = dihydrotetrabenazine; FDG = 
fluorodeoxyglucose; ROI = region of interest; SUVR = standardised uptake value ratio; MCBP = mean cortical binding potential; DVR = distribution volume 
ratio; SPM = statistical parametric mapping; FWE = family-wise error. 
Shimada et al. 
2012 (34) 
8 DLB 
7 PDD 
13 AD 
22 HC 
Not stated 
11
C-PIB PET 
MRI
 
90 min dynamic scan. 
Logan graphical analysis 
method. 
VOI DVR v. cerebellum. 
Mean cortical PiB DVR. 
4 cortical areas. 
PiB positive LBD subjects demonstrated 
cortical atrophy compared with HC; greater 
atrophy in parahippocampal regions than 
PiB –ve LBD subjects. 
Gomperts et 
al. 2013 (37) 
35 PD 
11 PD-MCI 
Not stated 
11
C-PIB PET 
 
60 min dynamic scan. 
Logan graphical analysis 
method.  DVR v. 
cerebellum. 
Precuneus, frontal cortex 
and striatum. 
Higher PiB retention at baseline associated 
with progression to MCI or dementia and 
with deterioration in executive function. 
Motor deterioration not linked to baseline 
striatal or precuneus amyloid burden.  
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*Includes control subjects that were excluded from analysis because of high cortical Aβ ligand binding 
PiB=Pittsburgh compound-B; DVR=distribution volume ratio; MCBP=mean cortical binding potential; SUVR=standard uptake volume ratio 
 
Table 2.Cortical amyloid burden classification (positive or negative) by diagnostic group 
Study DLB PDD PD PD-MCI AD Control Method of classification 
 +ve -ve +ve -ve +ve -ve +ve -ve +ve -ve +ve -ve  
Edison et al. 2008* 
(23) 
11 2 2 10 0 10 - - - - 6* 41 
PiB uptake ratio >2SD above control mean 
in 1  or more cortical regions 
Gomperts et al. 
2008 (24) 
7 1 7 0 7 4 - - 15 0 19 18 DVR >1.3 in 50+ cortical voxels 
Maetzler et al. 
2008 (31) 
- - 2 8 - - - - 6 6 0 11 Visual inspection 
Maetzler et al. 
2009 (33) 
4 5 4 8 0 14 - - - - - - SUVR >1.45/<1.38 
Jokinen et al. 2010 
(35) 
- - 3 8 0 8 - - - - 2 22 
Cortical SUVR >1.5 in 1 or more cortical 
regions 
Foster et al. 2010 
(27) 
2 4 4 11 1 7 1 8 - - 1 8 MCBP ≥0.2 
Villemagne et al. 
2011 (28) 
2 5 - - 0 5 - - 29 1 5 27 SUVR  >1.4 
Graff-Radford et al. 
2012 (38) 
3 4 - - - - - - - - - - Global cortical PiB retention ratio >1.5 
Kantarci et al. 2012 
(26) 
11 10 - - - - - - 19 2 9 33 Global cortical PiB retention ratio >1.5 
Petrou et al. 2012 
(32) 
- - 4 1 0 5 2 28 - - - - Visual inspection 
Ossenkoppele et 
al. 2012* (43) 
4 1 - - - - - - 40 26 - - Visual inspection 
Shimada et al. 
2012 (34) 
4 4 2 5 - - - - 13 0 5* 17 
DVR >2 SD above HC mean in one or more 
cortical region. 
Total 48 36 28 51 8 53 3 36 122 35 47 177  
% +ve 57 35 13 8 78 21  
19 
 
References 
1. McKeith IG, Galasko D, Kosaka K, et al: Consensus guidelines for the clinical and pathologic 
diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international 
workshop. Neurology 1996; 47:1113-1124 
2. Stevens T, Livingston G, Kitchen G, et al: Islington study of dementia subtypes in the 
community. British Journal of Psychiatry 2002; 180:270-276 
3. Emre M, Aarsland D, Brown R, et al: Clinical diagnostic criteria for dementia associated with 
Parkinson's disease. Mov Disord 2007; 22:1689-1707; quiz 1837 
4. McKeith IG, Dickson DW, Lowe J, et al: Diagnosis and management of dementia with Lewy 
bodies: third report of the DLB Consortium. Neurology 2005; 65:1863-1872 
5. McKeith I: Commentary: DLB and PDD: the same or different? Is there a debate? Int 
Psychogeriatr 2009; 21:220-224 
6. Kovari E, Horvath J,Bouras C: Neuropathology of Lewy body disorders. Brain Res Bull 2009; 
80:203-210 
7. Merdes AR, Hansen LA, Jeste DV, et al: Influence of Alzheimer pathology on clinical 
diagnostic accuracy in dementia with Lewy bodies. Neurology 2003; 60:1586-1590 
8. Weisman D, Cho M, Taylor C, et al: In dementia with Lewy bodies, Braak stage determines 
phenotype, not Lewy body distribution. Neurology 2007; 69:356-359 
9. Del Ser T, Hachinski V, Merskey H, et al: Clinical and pathologic features of two groups of 
patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer 
Dis Assoc Disord 2001; 15:31-44 
10. Nelson PT, Kryscio RJ, Jicha GA, et al: Relative preservation of MMSE scores in autopsy-
proven dementia with Lewy bodies. Neurology 2009; 73:1127-1133 
11. Ballard C, Ziabreva I, Perry R, et al: Differences in neuropathologic characteristics across the 
Lewy body dementia spectrum. Neurology 2006; 67:1931-1934 
12. Fujishiro H, Iseki E, Higashi S, et al: Distribution of cerebral amyloid deposition and its 
relevance to clinical phenotype in Lewy body dementia. Neurosci Lett 2010; 486:19-23 
13. Selikhova M, Williams DR, Kempster PA, et al: A clinico-pathological study of subtypes in 
Parkinson's disease. Brain 2009; 132:2947-2957 
14. Aarsland D, Ballard CG,Halliday G: Are Parkinson's disease with dementia and dementia with 
Lewy bodies the same entity? J Geriatr Psychiatry Neurol 2004; 17:137-145 
15. Jellinger KA, Seppi K,Wenning GK: Clinical and neuropathological correlates of Lewy body 
disease. Acta Neuropathol 2003; 106:188-189; author reply 190 
16. Pletnikova O, West N, Lee MK, et al: Abeta deposition is associated with enhanced cortical 
alpha-synuclein lesions in Lewy body diseases. Neurobiol Aging 2005; 26:1183-1192 
17. Rowe CC,Villemagne VL: Brain amyloid imaging. J Nucl Med 2011; 52:1733-1740 
18. Sojkova J, Driscoll I, Iacono D, et al: In vivo fibrillar beta-amyloid detected using [11C]PiB 
positron emission tomography and neuropathologic assessment in older adults. Arch Neurol 2011; 
68:232-240 
19. Clark CM, Schneider JA, Bedell BJ, et al: Use of florbetapir-PET for imaging beta-amyloid 
pathology. JAMA 2011; 305:275-283 
20. Ikonomovic MD, Klunk WE, Abrahamson EE, et al: Post-mortem correlates of in vivo PiB-PET 
amyloid imaging in a typical case of Alzheimer's disease. Brain 2008; 131:1630-1645 
20 
 
21. Quigley H, Colloby SJ,O'Brien JT: PET imaging of brain amyloid in dementia: a review. Int J 
Geriatr Psychiatry 2011; 26:991-999 
22. Rosenberg PB, Wong DF, Edell SL, et al: Cognition and Amyloid Load in Alzheimer Disease 
Imaged With Florbetapir F 18(AV-45) Positron Emission Tomography. Am J Geriatr Psychiatry 2013; 
21:272-278 
23. Edison P, Rowe CC, Rinne JO, et al: Amyloid load in Parkinson's disease dementia and Lewy 
body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg 
Psychiatry 2008; 79:1331-1338 
24. Gomperts SN, Rentz DM, Moran E, et al: Imaging amyloid deposition in Lewy body diseases. 
Neurology 2008; 71:903-910 
25. Gomperts SN, Locascio JJ, Marquie M, et al: Brain amyloid and cognition in Lewy body 
diseases. Movement Disorders 2012; 27:965-973 
26. Kantarci K, Lowe VJ, Boeve BF, et al: Multimodality imaging characteristics of dementia with 
Lewy bodies. Neurobiol Aging 2012; 33:2091-2105 
27. Foster ER, Campbell MC, Burack MA, et al: Amyloid imaging of Lewy body-associated 
disorders. Mov Disord 2010; 25:2516-2523 
28. Villemagne VL, Ong K, Mulligan RS, et al: Amyloid Imaging with F-18-Florbetaben in 
Alzheimer Disease and Other Dementias. Journal of Nuclear Medicine 2011; 52:1210-1217 
29. Claassen DO, Lowe VJ, Peller PJ, et al: Amyloid and glucose imaging in dementia with Lewy 
bodies and multiple systems atrophy. Parkinsonism Relat Disord 2011; 17:160-165 
30. Rowe CC, Ng S, Ackermann U, et al: Imaging beta-amyloid burden in aging and dementia. 
Neurology 2007; 68:1718-1725 
31. Maetzler W, Reimold M, Liepelt I, et al: [11C]PIB binding in Parkinson's disease dementia. 
Neuroimage 2008; 39:1027-1033 
32. Petrou M, Bohnen NI, Muller ML, et al: Abeta-amyloid deposition in patients with Parkinson 
disease at risk for development of dementia. Neurology 2012; 79:1161-1167 
33. Maetzler W, Liepelt I, Reimold M, et al: Cortical PIB binding in Lewy body disease is 
associated with Alzheimer-like characteristics. Neurobiol Dis 2009; 34:107-112 
34. Shimada H, Shinotoh H, Hirano S, et al: beta-amyloid in lewy body disease is related to 
Alzheimer's disease-like atrophy. Mov Disord In Press;  
35. Jokinen P, Scheinin N, Aalto S, et al: [(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients 
with Parkinson's disease with and without dementia. Parkinsonism Relat Disord 2010; 16:666-670 
36. Johansson A, Savitcheva I, Forsberg A, et al: [(11)C]-PIB imaging in patients with Parkinson's 
disease: preliminary results. Parkinsonism Relat Disord 2008; 14:345-347 
37. Gomperts SN, Locascio JJ, Rentz D, et al: Amyloid is linked to cognitive decline in patients 
with Parkinson disease without dementia. Neurology 2013; 80:85-91 
38. Graff-Radford J, Boeve BF, Pedraza O, et al: Imaging and acetylcholinesterase inhibitor 
response in dementia with Lewy bodies. Brain 2012; 135:2470-2477 
39. Fleisher AS, Chen K, Liu X, et al: Apolipoprotein E epsilon4 and age effects on florbetapir 
positron emission tomography in healthy aging and Alzheimer disease. Neurobiol Aging 2013; 34:1-
12 
40. Drzezga A, Grimmer T, Henriksen G, et al: Effect of APOE genotype on amyloid plaque load 
and gray matter volume in Alzheimer disease. Neurology 2009; 72:1487-1494 
41. Sinha N, Firbank M,O'Brien JT: Biomarkers in dementia with Lewy bodies: a review. Int J 
Geriatr Psychiatry 2012; 27:443-453 
21 
 
42. Burke JF, Albin RL, Koeppe RA, et al: Assessment of mild dementia with amyloid and 
dopamine terminal positron emission tomography. Brain 2011; 134:1647-1657 
43. Ossenkoppele R, Prins ND, Pijnenburg YA, et al: Impact of molecular imaging on the 
diagnostic process in a memory clinic. Alzheimers Dement In Press;  
44. Bacskai BJ, Frosch MP, Freeman SH, et al: Molecular imaging with Pittsburgh Compound B 
confirmed at autopsy: a case report. Arch Neurol 2007; 64:431-434 
45. Burack MA, Hartlein J, Flores HP, et al: In vivo amyloid imaging in autopsy-confirmed 
Parkinson disease with dementia. Neurology 2010; 74:77-84 
46. Kantarci K, Yang C, Schneider JA, et al: Ante mortem amyloid imaging and beta-amyloid 
pathology in a case with dementia with Lewy bodies. Neurobiol Aging 2012; 33:878-885 
47. Ikonomovic MD, Abrahamson EE, Price JC, et al: Early AD pathology in a C-11 PiB-negative 
case: a PiB-amyloid imaging, biochemical, and immunohistochemical study. Acta Neuropathol 2012; 
123:433-447 
48. Harding AJ,Halliday GM: Cortical Lewy body pathology in the diagnosis of dementia. Acta 
Neuropathol 2001; 102:355-363 
49. Jellinger KA,Attems J: Prevalence and impact of vascular and Alzheimer pathologies in Lewy 
body disease. Acta Neuropathol 2008; 115:427-436 
50. Compta Y, Parkkinen L, O'Sullivan SS, et al: Lewy- and Alzheimer-type pathologies in 
Parkinson's disease dementia: which is more important? Brain 2011; 134:1493-1505 
51. Irwin DJ, White MT, Toledo JB, et al: Neuropathologic substrates of Parkinson disease 
dementia. Ann Neurol 2012; 72:587-598 
52. Mirra SS, Heyman A, McKeel D, et al: The Consortium to Establish a Registry for Alzheimer's 
Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. 
Neurology 1991; 41:479-486 
53. Kempster PA, Williams DR, Selikhova M, et al: Patterns of levodopa response in Parkinson's 
disease: a clinico-pathological study. Brain 2007; 130:2123-2128 
54. Jellinger KA, Seppi K, Wenning GK, et al: Impact of coexistent Alzheimer pathology on the 
natural history of Parkinson's disease. J Neural Transm 2002; 109:329-339 
55. Aarsland D, Perry R, Brown A, et al: Neuropathology of dementia in Parkinson's disease: a 
prospective, community-based study. Ann Neurol 2005; 58:773-776 
56. Lashley T, Holton JL, Gray E, et al: Cortical alpha-synuclein load is associated with amyloid-
beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathol 2008; 115:417-425 
57. Ballard CG, Jacoby R, Del Ser T, et al: Neuropathological substrates of psychiatric symptoms 
in prospectively studied patients with autopsy-confirmed dementia with lewy bodies. Am J 
Psychiatry 2004; 161:843-849 
58. Masliah E, Rockenstein E, Veinbergs I, et al: beta-amyloid peptides enhance alpha-synuclein 
accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and 
Parkinson's disease. Proc Natl Acad Sci U S A 2001; 98:12245-12250 
59. Clinton LK, Blurton-Jones M, Myczek K, et al: Synergistic Interactions between Abeta, tau, 
and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci 2010; 
30:7281-7289 
60. Serby M, Brickman AM, Haroutunian V, et al: Cognitive burden and excess Lewy-body 
pathology in the Lewy-body variant of Alzheimer disease. Am J Geriatr Psychiatry 2003; 11:371-374 
61. Kraybill ML, Larson EB, Tsuang DW, et al: Cognitive differences in dementia patients with 
autopsy-verified AD, Lewy body pathology, or both. Neurology 2005; 64:2069-2073 
22 
 
62. Mattila PM, Rinne JO, Helenius H, et al: Alpha-synuclein-immunoreactive cortical Lewy 
bodies are associated with cognitive impairment in Parkinson's disease. Acta Neuropathol 2000; 
100:285-290 
63. Braak H, Rub U, Jansen Steur EN, et al: Cognitive status correlates with neuropathologic 
stage in Parkinson disease. Neurology 2005; 64:1404-1410 
64. Sabbagh MN, Adler CH, Lahti TJ, et al: Parkinson disease with dementia: comparing patients 
with and without Alzheimer pathology. Alzheimer Dis Assoc Disord 2009; 23:295-297 
65. Aarsland D, Kvaloy JT, Andersen K, et al: The effect of age of onset of PD on risk of dementia. 
J Neurol 2007; 254:38-45 
66. Moghbel MC, Saboury B, Basu S, et al: Amyloid-beta imaging with PET in Alzheimer's disease: 
is it feasible with current radiotracers and technologies? Eur J Nucl Med Mol Imaging 2012; 39:202-
208 
67. Villemagne VL, Klunk WE, Mathis CA, et al: A beta Imaging: feasible, pertinent, and vital to 
progress in Alzheimer's disease. Eur J Nucl Med Mol Imaging 2012; 39:209-219 
68. Svedberg MM, Hall H, Hellstrom-Lindahl E, et al: [(11)C]PIB-amyloid binding and levels of 
Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients. Neurochem Int 2009; 
54:347-357 
69. Driscoll I, Troncoso JC, Rudow G, et al: Correspondence between in vivo (11)C-PiB-PET 
amyloid imaging and postmortem, region-matched assessment of plaques. Acta Neuropathol 2012; 
124:823-831 
70. Herholz K,Ebmeier K: Clinical amyloid imaging in Alzheimer's disease. Lancet Neurol 2011; 
10:667-670 
71. Fujishiro H, Ferman TJ, Boeve BF, et al: Validation of the neuropathologic criteria of the third 
consortium for dementia with Lewy bodies for prospectively diagnosed cases. J Neuropathol Exp 
Neurol 2008; 67:649-656 
72. Burton EJ, Barber R, Mukaetova-Ladinska EB, et al: Medial temporal lobe atrophy on MRI 
differentiates Alzheimer's disease from dementia with Lewy bodies and vascular cognitive 
impairment: a prospective study with pathological verification of diagnosis. Brain 2009; 132:195-203 
73. Whitwell JL, Josephs KA, Murray ME, et al: MRI correlates of neurofibrillary tangle pathology 
at autopsy: a voxel-based morphometry study. Neurology 2008; 71:743-749 
74. Braak H,Braak E: Neuropathological stageing of Alzheimer-related changes. Acta 
Neuropathol 1991; 82:239-259 
 
23 
 
 
